1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation
Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further increasing the treatment burden for people with T2D. This real-world study assessed the efficacy and safety of switching from BBI to iGlarLixi, a once...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73, p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 73 |
| creator | Giorgino, Francesco Lauand, Felipe Servera, Soraly Li, Xuan Taybani, Zoltán Cheng, Alice YY Fonseca, Vivian Tebaibia, Amar Anaforoglu, Inan |
| description | Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further increasing the treatment burden for people with T2D. This real-world study assessed the efficacy and safety of switching from BBI to iGlarLixi, a once-daily fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide, in people with T2D. Methods: This real-world retrospective study included people with T2D (≥18 years) who received ≥1 iGlarLixi prescription during the identification (ID) period following prior treatment with BBI using the Optum Market Clarity® electronic medical record dataset of people with T2D from the United States. The primary endpoint was HbA1c change at 6 months. Secondary endpoints were HbA1c change at 3 months, BW change and hypoglycemic event rate at 6 months. Results: In total, 11,887 people received ≥1 iGlarLixi prescription during the ID period, and of these, 372 had switched from a BBI regimen to iGlarLixi (mean age, 59 years; mean baseline HbA1c, 9.55%; mean baseline BW, 101.9 kg). From baseline to Month 6, switching to iGlarLixi resulted in a significant mean HbA1c reduction of −0.93% (95% confidence interval [CI]: −1.13, −0.74; p |
| doi_str_mv | 10.2337/db24-1867-LB |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_3100300778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3100300778</sourcerecordid><originalsourceid>FETCH-proquest_journals_31003007783</originalsourceid><addsrcrecordid>eNqNzM1Kw0AUBeBBFKw_Ox_gguvRSUY6jbvW1h8oKLagu3Kb3Jgp40zMnaDZ-Q4-jO_jkxihDyBncRbn4whxkqizVGtzXqzTC5mMhkbOJztikGQ6kzo1z7tioFSSysRkZl8cMG-UUsM-A_G95ZcwhkdCJ59C4wpYxLboYMxMzNa_QKwIZmVpc8w7QN8DLCl2EEpYvNuYV3-obMIrTJDR_Xx-TYJrGe48t856WFbUYN1BDHDvc5JTtK4De-OwmdsPCz15oFA7gv6tgmVXE6QwtbimSCwXwVmYkiTO0WG0wR-JvRId0_G2D8Xp9Wx5dSvrJry1xHG1CW3j-2mlE6W0UsaM9P_UL2VlaHY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3100300778</pqid></control><display><type>article</type><title>1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Giorgino, Francesco ; Lauand, Felipe ; Servera, Soraly ; Li, Xuan ; Taybani, Zoltán ; Cheng, Alice YY ; Fonseca, Vivian ; Tebaibia, Amar ; Anaforoglu, Inan</creator><creatorcontrib>Giorgino, Francesco ; Lauand, Felipe ; Servera, Soraly ; Li, Xuan ; Taybani, Zoltán ; Cheng, Alice YY ; Fonseca, Vivian ; Tebaibia, Amar ; Anaforoglu, Inan</creatorcontrib><description>Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further increasing the treatment burden for people with T2D. This real-world study assessed the efficacy and safety of switching from BBI to iGlarLixi, a once-daily fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide, in people with T2D. Methods: This real-world retrospective study included people with T2D (≥18 years) who received ≥1 iGlarLixi prescription during the identification (ID) period following prior treatment with BBI using the Optum Market Clarity® electronic medical record dataset of people with T2D from the United States. The primary endpoint was HbA1c change at 6 months. Secondary endpoints were HbA1c change at 3 months, BW change and hypoglycemic event rate at 6 months. Results: In total, 11,887 people received ≥1 iGlarLixi prescription during the ID period, and of these, 372 had switched from a BBI regimen to iGlarLixi (mean age, 59 years; mean baseline HbA1c, 9.55%; mean baseline BW, 101.9 kg). From baseline to Month 6, switching to iGlarLixi resulted in a significant mean HbA1c reduction of −0.93% (95% confidence interval [CI]: −1.13, −0.74; p<0.0001) to 8.61% (n=372). At Month 3, HbA1c was 8.68% (n=204). The mean change in BW at 6 months was −0.89 kg (95% CI: −1.61, −0.18; n=359). The hypoglycemia event rate was 46.24 per 100 person-years of follow-up (P100PYFU) at baseline and 40.32 P100PYFU (event rate ratio: 0.77; 95% CI: 0.57, 1.05) after 6 months of iGlarLixi treatment. Conclusion: In a real-world setting, people with T2D and elevated HbA1c switching from a BBI regimen to a once-daily injection of iGlarLixi achieved lower HbA1c, weight benefit and numerically lower hypoglycemic events.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-1867-LB</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Body weight ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Electronic medical records ; Hypoglycemia ; Insulin</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Giorgino, Francesco</creatorcontrib><creatorcontrib>Lauand, Felipe</creatorcontrib><creatorcontrib>Servera, Soraly</creatorcontrib><creatorcontrib>Li, Xuan</creatorcontrib><creatorcontrib>Taybani, Zoltán</creatorcontrib><creatorcontrib>Cheng, Alice YY</creatorcontrib><creatorcontrib>Fonseca, Vivian</creatorcontrib><creatorcontrib>Tebaibia, Amar</creatorcontrib><creatorcontrib>Anaforoglu, Inan</creatorcontrib><title>1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation</title><title>Diabetes (New York, N.Y.)</title><description>Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further increasing the treatment burden for people with T2D. This real-world study assessed the efficacy and safety of switching from BBI to iGlarLixi, a once-daily fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide, in people with T2D. Methods: This real-world retrospective study included people with T2D (≥18 years) who received ≥1 iGlarLixi prescription during the identification (ID) period following prior treatment with BBI using the Optum Market Clarity® electronic medical record dataset of people with T2D from the United States. The primary endpoint was HbA1c change at 6 months. Secondary endpoints were HbA1c change at 3 months, BW change and hypoglycemic event rate at 6 months. Results: In total, 11,887 people received ≥1 iGlarLixi prescription during the ID period, and of these, 372 had switched from a BBI regimen to iGlarLixi (mean age, 59 years; mean baseline HbA1c, 9.55%; mean baseline BW, 101.9 kg). From baseline to Month 6, switching to iGlarLixi resulted in a significant mean HbA1c reduction of −0.93% (95% confidence interval [CI]: −1.13, −0.74; p<0.0001) to 8.61% (n=372). At Month 3, HbA1c was 8.68% (n=204). The mean change in BW at 6 months was −0.89 kg (95% CI: −1.61, −0.18; n=359). The hypoglycemia event rate was 46.24 per 100 person-years of follow-up (P100PYFU) at baseline and 40.32 P100PYFU (event rate ratio: 0.77; 95% CI: 0.57, 1.05) after 6 months of iGlarLixi treatment. Conclusion: In a real-world setting, people with T2D and elevated HbA1c switching from a BBI regimen to a once-daily injection of iGlarLixi achieved lower HbA1c, weight benefit and numerically lower hypoglycemic events.</description><subject>Body weight</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Electronic medical records</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNzM1Kw0AUBeBBFKw_Ox_gguvRSUY6jbvW1h8oKLagu3Kb3Jgp40zMnaDZ-Q4-jO_jkxihDyBncRbn4whxkqizVGtzXqzTC5mMhkbOJztikGQ6kzo1z7tioFSSysRkZl8cMG-UUsM-A_G95ZcwhkdCJ59C4wpYxLboYMxMzNa_QKwIZmVpc8w7QN8DLCl2EEpYvNuYV3-obMIrTJDR_Xx-TYJrGe48t856WFbUYN1BDHDvc5JTtK4De-OwmdsPCz15oFA7gv6tgmVXE6QwtbimSCwXwVmYkiTO0WG0wR-JvRId0_G2D8Xp9Wx5dSvrJry1xHG1CW3j-2mlE6W0UsaM9P_UL2VlaHY</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Giorgino, Francesco</creator><creator>Lauand, Felipe</creator><creator>Servera, Soraly</creator><creator>Li, Xuan</creator><creator>Taybani, Zoltán</creator><creator>Cheng, Alice YY</creator><creator>Fonseca, Vivian</creator><creator>Tebaibia, Amar</creator><creator>Anaforoglu, Inan</creator><general>American Diabetes Association</general><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240601</creationdate><title>1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation</title><author>Giorgino, Francesco ; Lauand, Felipe ; Servera, Soraly ; Li, Xuan ; Taybani, Zoltán ; Cheng, Alice YY ; Fonseca, Vivian ; Tebaibia, Amar ; Anaforoglu, Inan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_31003007783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Body weight</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Electronic medical records</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giorgino, Francesco</creatorcontrib><creatorcontrib>Lauand, Felipe</creatorcontrib><creatorcontrib>Servera, Soraly</creatorcontrib><creatorcontrib>Li, Xuan</creatorcontrib><creatorcontrib>Taybani, Zoltán</creatorcontrib><creatorcontrib>Cheng, Alice YY</creatorcontrib><creatorcontrib>Fonseca, Vivian</creatorcontrib><creatorcontrib>Tebaibia, Amar</creatorcontrib><creatorcontrib>Anaforoglu, Inan</creatorcontrib><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giorgino, Francesco</au><au>Lauand, Felipe</au><au>Servera, Soraly</au><au>Li, Xuan</au><au>Taybani, Zoltán</au><au>Cheng, Alice YY</au><au>Fonseca, Vivian</au><au>Tebaibia, Amar</au><au>Anaforoglu, Inan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-01</date><risdate>2024</risdate><volume>73</volume><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further increasing the treatment burden for people with T2D. This real-world study assessed the efficacy and safety of switching from BBI to iGlarLixi, a once-daily fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide, in people with T2D. Methods: This real-world retrospective study included people with T2D (≥18 years) who received ≥1 iGlarLixi prescription during the identification (ID) period following prior treatment with BBI using the Optum Market Clarity® electronic medical record dataset of people with T2D from the United States. The primary endpoint was HbA1c change at 6 months. Secondary endpoints were HbA1c change at 3 months, BW change and hypoglycemic event rate at 6 months. Results: In total, 11,887 people received ≥1 iGlarLixi prescription during the ID period, and of these, 372 had switched from a BBI regimen to iGlarLixi (mean age, 59 years; mean baseline HbA1c, 9.55%; mean baseline BW, 101.9 kg). From baseline to Month 6, switching to iGlarLixi resulted in a significant mean HbA1c reduction of −0.93% (95% confidence interval [CI]: −1.13, −0.74; p<0.0001) to 8.61% (n=372). At Month 3, HbA1c was 8.68% (n=204). The mean change in BW at 6 months was −0.89 kg (95% CI: −1.61, −0.18; n=359). The hypoglycemia event rate was 46.24 per 100 person-years of follow-up (P100PYFU) at baseline and 40.32 P100PYFU (event rate ratio: 0.77; 95% CI: 0.57, 1.05) after 6 months of iGlarLixi treatment. Conclusion: In a real-world setting, people with T2D and elevated HbA1c switching from a BBI regimen to a once-daily injection of iGlarLixi achieved lower HbA1c, weight benefit and numerically lower hypoglycemic events.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-1867-LB</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_3100300778 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Body weight Diabetes Diabetes mellitus (non-insulin dependent) Electronic medical records Hypoglycemia Insulin |
| title | 1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T00%3A29%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1867-LB:%20A%20Real-World%20Study%20Assessing%20the%20Efficacy%20and%20Safety%20of%20Switching%20from%20Basal%E2%80%93Bolus%20Insulin%20Therapy%20to%20Once-Daily%20iGlarLixi%20in%20People%20with%20Type%202%20Diabetes-Soli%20De-escalation&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=Giorgino,%20Francesco&rft.date=2024-06-01&rft.volume=73&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-1867-LB&rft_dat=%3Cproquest%3E3100300778%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3100300778&rft_id=info:pmid/&rfr_iscdi=true |